Emedastine difumarate: A review of its potential ameliorating effect for tissue remodeling in allergic diseases

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1859-1867

  Murota, Hiroyuki ^a   Katayama, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Allergic rhinitis; Atopic dermatitis; Emedastine difumarate; Fibroblast; Tissue remodeling

Indexed keywords

CETIRIZINE; DEXCHLORPHENIRAMINE MALEATE; EMEDASTINE; HISTAMINE; KETOTIFEN FUMARATE;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG SAFETY; FIBROBLAST; HUMAN; IN VITRO SELECTION; NONHUMAN; REVIEW; SKIN ALLERGY; URTICARIA;

ANIMALS; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; INFLAMMATION; SKIN;

EID: 68149181539     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903078410     Document Type: Review

References (77)

1. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006;533:69-76
2. Hatamochi A, Ueki H, Mauch C, et al. Effect of histamine on collagen and collagen m-RNA production in human skin fibroblasts. J Dermatol Sci 1991;2:407-412 • This paper provides the first evidence of the fibrogenic effect of histamine.
3. Abe M, Yokoyama Y, Amano H, et al. Effect of activated human mast cells and mast cell-derived mediators on proliferation, type I collagen production and glycosaminoglycans synthesis by human dermal fibroblasts. Eur J Dermatol 2002;12:340-346 (Pubitemid 34713099)
4. Murota H, Bae S, Hamasaki Y, et al. Emedastine difumarate inhibits histamine-induced collagen synthesis in dermal fibroblasts. J Investig Allergol Clin Immunol 2008;18:245-252 • This is a recent study demonstrating that histamine has heterogeneous effects on type 1 collagen synthesis and is efficiently inhibited by emedastine difumarate. (Pubitemid 352031568)
5. Katayama I, Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. J Dermatol Sci 1997;15:201-206 (Pubitemid 27390886)
6. Numata Y, Terui T, Okuyama R, et al. The accelerating effect of histamine on the cutaneous wound-healing process through the action of basic fibroblast growth factor. J Invest Dermatol 2006;126:1403-1409 (Pubitemid 43997925)
7. Sykes JB. The concise Oxford dictionary. New York: Oxford University Press, 1986
8. Bousquet J, Jacot W, Vignola AM, et al. Allergic rhinitis: a disease remodeling the upper airways? J Allergy Clin Immunol 2004;113:43-49
9. Ohno I, Ohtani H, Nitta Y, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997;16:212-219 (Pubitemid 127497442)
10. Lemjabbar H, Gosset P, Lamblin C, et al. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med 1999;159:1298-1307 (Pubitemid 29202571)
11. Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest 2003;123:417S-22S
12. Hoshino M, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998;102:783-788 (Pubitemid 28543528)
13. Salib RJ, Howarth PH. Remodelling of the upper airways in allergic rhinitis: is it a feature of the disease? Clin Exp Allergy 2003;33:1629-1633 • This is a worthwhile review because the authors introduce the mechanisms of tissue remodeling in an integrated manner by comparing asthma and rhinitis.
14. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58:621-623 (Pubitemid 36831317)
15. Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol 2002;41:701-706 (Pubitemid 35252053)
16. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:311-317 (Pubitemid 29503666)
17. Spector SL, Shikiar R, Harding G, et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007;79:157-162
18. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43:24-30
19. Davies DE, Wicks J, Powell RM, et al. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003;111:215-25; quiz 26 (Pubitemid 36228538)
20. Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995;96:302-18; quiz 19 • This is a worthwhile review because the authors see atopic dermatitis from a broad perspective.
21. Trautmann A, Schmid-Grendelmeier P, Kruger K, et al. T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol 2002;109:329-337 (Pubitemid 34158302)
22. White SR. Epithelium as a target. Philadelphia: Lippincott-Raven, 1997
23. Tschumperlin DJ, Drazen JM. Mechanical stimuli to airway remodeling. Am J Respir Crit Care Med 2001;164:S90-4
24. Roche WR, Beasley R, Williams JH, et al. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;1:520-524
25. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405-410 (Pubitemid 23044915)
26. O'Byrne PM, Gauvreau GM, Brannan JD. Provoked models of asthma: what have we learnt? Clin Exp Allergy 2009;39:181-192
27. Kunzmann S, Schmidt-Weber C, Zingg JM, et al. Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: potential role of histamine in airway remodeling. J Allergy Clin Immunol 2007;119:1398-1407 (Pubitemid 46855848)
28. Hebda PA, Collins MA, Tharp MD. Mast cell and myofibroblast in wound healing. Dermatol Clin 1993;11:685-696
29. Artuc M, Hermes B, Steckelings UM, et al. Mast cells and their mediators in cutaneous wound healing: active participants or innocent bystanders? Exp Dermatol 1999;8:1-16
30. Trautmann A, Toksoy A, Engelhardt E, et al. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo. J Pathol 2000;190:100-106 (Pubitemid 30053360)
31. Noli C, Miolo A. The mast cell in wound healing. Vet Dermatol 2001;12:303-313
32. Gailit J, Marchese MJ, Kew RR, et al. The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol 2001;117:1113-1119 (Pubitemid 34205906)
33. Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J 2006;20:2366-2368 • This is an important study demonstrating the contribution of H1 receptor-mediated signaling on tissue remodeling in skin.
34. Katayama I, Yokozeki H, Nishioka K. Mast-cell-derived mediators induce epidermal cell proliferation: clue for lichenified skin lesion formation in atopic dermatitis. Int Arch Allergy Immunol 1992;98:410-414
35. Maurer M, Opitz M, Henz BM, et al. The mast cell products histamine and serotonin stimulate and TNF-alpha inhibits the proliferation of murine epidermal keratinocytes in situ. J Dermatol Sci 1997;16:79-84 (Pubitemid 28004778)
36. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134:1842-1860
37. Ishihara Y, Okabe S. Effects of antiulcer agents on healing of mepirizole-induced duodenal ulcers in rats. Digestion 1983;27:29-35
38. Tsuchida T, Tsukamoto Y, Segawa K, et al. Effects of cimetidine and omeprazole on angiogenesis in granulation tissue of acetic acid-induced gastric ulcers in rats. Digestion 1990;47:8-14
39. Antoine M, Wirz W, Tag CG, et al. Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun 2006;346:224-233 (Pubitemid 43865988)
40. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95:11709-11714 (Pubitemid 28460479)
41. Werner S, Alzheimer C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev 2006;17:157-171 (Pubitemid 43816894)
42. Takehara K. Growth regulation of skin fibroblasts. J Dermatol Sci 2000;24(Suppl 1):S70-7
43. Wozney JM. Bone morphogenetic proteins. Prog Growth Factor Res 1989;1:267-280
44. Mou C, Jackson B, Schneider P, et al. Generation of the primary hair follicle pattern. Proc Natl Acad Sci USA 2006;103:9075-9080 (Pubitemid 43902535)
45. Lim MC, Taylor RM, Naclerio RM. The histology of allergic rhinitis and its comparison to cellular changes in nasal lavage. Am J Respir Crit Care Med 1995;151:136-144
46. van Toorenenbergen AW, Gerth van Wijk R, Vermeulen AM. Allergen-induced matrix metalloproteinase-9 in nasal lavage fluid. Allergy 1999;54:293-294
47. Sanai A, Nagata H, Konno A. Extensive interstitial collagen deposition on the basement membrane zone in allergic nasal mucosa. Acta Otolaryngol 1999;119:473-478 (Pubitemid 29336455)
48. Shimizu T, Kanai K, Asano K, et al. Suppression of matrix metalloproteinase production in nasal fibroblasts by tranilast, an antiallergic agent, in vitro. Mediators Inflamm 2005;2005:150-159 (Pubitemid 41381523)
49. Asano K, Kanai KI, Suzaki H. Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin Exp Allergy 2004;34:1890-1898 (Pubitemid 40023640)
50. Shaida A, Kenyon G, Devalia J, et al. Matrix metalloproteinases and their inhibitors in the nasal mucosa of patients with perennial allergic rhinitis. J Allergy Clin Immunol 2001;108:791-796 (Pubitemid 33096212)
51. Leonardi A, Radice M, Fregona IA, et al. Histamine effects on conjunctival fibroblasts from patients with vernal conjunctivitis. Exp Eye Res 1999;68:739-746 (Pubitemid 29290793)
52. Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand Suppl 2000;230:18-21
53. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996;12:401-407
54. Fukuda T, Morimoto Y, Iemura R, et al. Effect of 1-(2-ethoxyethyl)-2-(4- methyl-1-homopiperazinyl)-benzimida zole difumarate (KB-2413), a new antiallergic, on chemical mediators. Arzneimittelforschung 1984;34:801-805 • This is an important study demonstrating the strong antihistaminic activity of emedastine difumarate. (Pubitemid 14084115)
55. Saito H, Yamamoto N, Tomita S, et al. Effect of emedastine difumarate on CC chemokine-elicited eosinophil migration. Int Arch Allergy Immunol 2001;125(Suppl 1):22-28 (Pubitemid 32620156)
56. Kohda F, Koga T, Uchi H, et al. Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-gamma and IL-4 in human keratinocytes. J Dermatol Sci 2002;28:34-41 (Pubitemid 34251058)
57. Saito T, Hagihara A, Igarashi N, et al. Inhibitory effects of emedastine difumarate on histamine release. Jpn J Pharmacol 1993;62:137-143 (Pubitemid 23218232)
58. Herranz U, Rusca A, Assandri A. Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Int J Clin Pharmacol Ther 2001;39:102-109 • This paper reports results of a well-conducted study emphasizing the cardiovascular safety of emedastine difumarate. (Pubitemid 32208537)
59. Brunner M, Kletter K, Assandri A, et al. Pharmacokinetic and mass balance study of unlabelled and (14)C-labelled emedastine difumarate in healthy volunteers. Xenobiotica 2002;32:761-770
60. Pons-Guiraud A, Nekam K, Lahovsky J, et al. Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial. Eur J Dermatol 2006;16:649-654 •• This paper reports on a well-designed study that revealed the efficacy of emedastine difumarate on chronic idiopathic urticaria. (Pubitemid 46202963)
61. Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1-20
62. Borazan M, Karalezli A, Akova YA, et al. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol 2008, doi:10.1111/j.1755-3768.01265.x •• The paper reports the results of a well-controlled study comparing the efficacy of olopatadine, ketotifen, epinastine, emedastine, and fluorometholone in providing relief of many symptoms of allergic conjunctivitis (e.g., itching, redness, tearing, chemosis).
63. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-228 (Pubitemid 40139383)
64. Orfeo V, Vardaro A, Lena P, et al. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Eur J Ophthalmol 2002;12:262-266
65. D'Arienzo PA, Leonardi A, Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2002;24:409-416 (Pubitemid 34275862)
66. Abelson MB, Kaplan AP. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model. Clin Ther 2002;24:445-456 (Pubitemid 34275865)
67. Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001;131:691-698 (Pubitemid 32522637)
68. Pinto CG, Lafuma A, Fagnani F, et al. Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. Pharmacoeconomics 2001;19:255-265 • This paper is of interest because it discusses the economic advantages of emedastine difumarate treatment for allergic conjunctivitis. (Pubitemid 32230940)
69. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000;130:717-723 (Pubitemid 32000852)
70. Secchi A, Ciprandi G, Leonardi A, et al. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl 2000;230:42-47
71. Secchi A, Leonardi A, Discepola M, et al. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl 2000;230:48-51
72. Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999;228:43-46 (Pubitemid 29196905)
73. Horak F, Stubner P, Zieglmayer R, et al. Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. Arzneimittelforschung 2004;54:666-672 •• This paper reports results of a well-designed study of the efficacy of emedastine difumarate for seasonal allergic rhinitis. (Pubitemid 39422844)
74. Yamagiwa M. Acoustic evaluation of the efficacy of medical therapy for allergic nasal obstruction. Eur Arch Otorhinolaryngol 1997;254(Suppl 1):S82-4 (Pubitemid 27110367)
75. Vermeeren A, Ramaekers JG, O'Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002;16:57-64 (Pubitemid 34273074)
76. Saito T, Fukuda T, Tajima S, et al. General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate. 2nd communication: Effects on the circulation and the other systems. Arzneimittelforschung 1988;38:267-272
77. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115:118-122